RecruitingNCT07594652
ADHD medication use in children with epilepsy
About this title
Read the official source — NCT07594652Medication studyAges 6–17United States
Understand this study
Who could participate?
Listed age limits: 6 years to 17 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 29, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 25
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT07594652
- Official title
Show the full official title
Use of JornayPM® to Treat ADHD in Pediatric Epilepsy
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Baltimore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Does this study involve medication?
Yes. The study involves medication, including methylphenidate hydrochloride (Jornay PM).
Who can participate?
Listed age limits: 6 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
